Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Abstract Individuals with chronic liver or kidney disease are at increased risk of severe COVID‐19. Molnupiravir is an orally administered antiviral authorized for the treatment of mild‐to‐moderate COVID‐19 in adults at risk of progression to severe disease. Two nonrandomized, open‐label, single‐dos...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kelly E. Duncan, Russ P. Carstens, Kristin L. Butterfield, Yoon Jin, Laura R. Inbody, Andrea K. Schaeffer, Catherine Z. Matthews, Tian Zhao, Shruti Patel, Brian M. Maas, Mickie H. Cheng, S. Aubrey Stoch
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.70073
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
by: Mickie H. Cheng, et al.
Published: (2025-04-01)

Correction: A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
by: Mickie H. Cheng, et al.
Published: (2025-05-01)

Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)

Pharmacokinetics of Molnupiravir in Cats with Naturally Occurring Feline Infectious Peritonitis
by: Petra Černá, et al.
Published: (2025-07-01)

Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
by: T. N. Komarov, et al.
Published: (2024-03-01)

Tolerability and pharmacokinetics of two antimony products after subcutaneous administration in dogs
by: Julie Rambaldi, et al.
Published: (2018-04-01)

BIOEQUIVALENCE STUDY OF GENERIC MOLNUPIRAVIR IN HEALTHY VOLUNTEERS
by: V. B. Vasilyuk, et al.
Published: (2023-02-01)

Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
by: Rani Sawtell, et al.
Published: (2025-12-01)

Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
by: Franco Wing Tak Cheng, et al.
Published: (2024-05-01)

Degree-Based and Neighborhood Degree Sum-Based Entropy Measures of Molnupiravir
by: Shibsankar Das, et al.
Published: (2025-06-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19
by: Akshita Chawla, et al.
Published: (2025-04-01)

Preclinical studies of antiviral activity of the RPH-137 fusion protein and molnupiravir against COVID-19
by: E. V. Shipaeva, et al.
Published: (2022-12-01)

A cost-effectiveness analysis of Molnupiravir and Paxlovid for outpatient treatment of COVID-19 in three African countries
by: Ijeoma P. Edoka, et al.
Published: (2025-06-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
by: Rebekah Penrice-Randal, et al.
Published: (2025-05-01)

Pharmacokinetics of Doxycycline in Alpacas After Intravenous and Subcutaneous Administration
by: José Martínez, et al.
Published: (2025-03-01)

Pharmacokinetic analysis of drugs vitamin D for oral administration
by: I. Yu. Torshin, et al.
Published: (2019-10-01)

Pharmacokinetics and Bioavailability of Doxycycline Following Parenteral Administration in Rabbits
by: Martínez José, et al.
Published: (2025-03-01)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Milvexian in Healthy Chinese Adults
by: Luo Z, et al.
Published: (2025-03-01)

Population-Based Propensity Score-Matched Analysis of Paxlovid and Molnupiravir Effectiveness in High-Risk COVID-19 Patients
by: Dr Yi-hsuan Chen, et al.
Published: (2025-03-01)

N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses.
by: Durbadal Ojha, et al.
Published: (2024-09-01)

THE STUDY OF THE PHARMACOKINETIC PROPERTIES OF 11-DEOXYMISOPROSTOL AFTER INTRAGASTRIC ADMINISTRATION
by: R. M. Kataeva, et al.
Published: (2019-03-01)

Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets
by: A Martso, et al.
Published: (2008-09-01)

Comparative analysis of pharmacokinetic parameters of transdermal and intramuscular administration of Galavit®
by: E. G. Kuznetsova, et al.
Published: (2021-07-01)

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan
by: Akira Yuasa, et al.
Published: (2025-02-01)

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
by: Yuchen Wei, et al.
Published: (2025-12-01)

Molnupiravir's real-world effectiveness in COVID-19 outpatients at high risk of severe disease: a single-center study
by: Ivana I Gmizic, et al.
Published: (2024-05-01)

Experimental Study of The Pharmacokinetics of Cefotaxime with Joint Administration of Drugs with Hyaluronidase Activity
by: M. V. Zhuravleva, et al.
Published: (2020-05-01)

Milk and Blood Pharmacokinetics of Tylosin and Tilmicosin following Parenteral Administrations to Cows
by: Tulay Avci, et al.
Published: (2014-01-01)

Pharmacokinetics of difloxacin after single intravenous, oral and intramuscular administration in pigeons
by: Yang-Guang Jin, et al.
Published: (2025-02-01)

The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats
by: Yuanxia Yang, et al.
Published: (2025-06-01)

Pharmacokinetics of Maternal Drug Administration: Insights into Placental Transfer and Fetal Exposure
by: Abdullah Duhaim, et al.
Published: (2024-12-01)

First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
by: Myung Jin Lee, et al.
Published: (2025-08-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-02-01)

A Phase 1 Study to Assess the Pharmacokinetics, Food Effect, Safety, and Tolerability of Sepiapterin in Healthy Japanese and Non-Japanese Participants
by: Lan Gao, et al.
Published: (2024-10-01)

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
by: Eric J Peters, et al.
Published: (2008-04-01)

Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular Dystrophy.
by: Valeria Ricotti, et al.
Published: (2016-01-01)

Open label clinical trial of orally administered molnupiravir as a first‐line treatment for naturally occurring effusive feline infectious peritonitis
by: Krystle L. Reagan, et al.
Published: (2024-11-01)